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Abstract
Background: Injection drug users (IDUs) represent a significant proportion of patients with chronic hepatitis C
(CHC). The low treatment uptake among these patients results in a low treatment effectiveness and a limited public
health impact. We hypothesised that a general practitioner (GP) providing an opioid maintenance treatment (OMT)
for addicted patients can achieve CHC treatment and sustained virological response rates (SVR) comparable to
patients without drug dependency.
Methods: Retrospective patient record analysis of 85 CHC patients who received OMT for more than 3 months in a
single-handed general practice in Zurich from January 1, 2002 through May 31, 2008. CHC treatment was based on
a combination with pegylated interferon and ribavirin. Treatment uptake and SVR (undetectable HCV RNA 6 months
after end of treatment) were assessed. The association between treatment uptake and patient characteristics was
investigated by multiple logistic regression.
Results: In 35 out of 85 CHC patients (52 males) with a median (IQR) age of 38.8 (35.0-44.4) years, antiviral therapy
was started (41.2%). Median duration (IQR) of OMT in the treatment group was 55.0 (35.0-110.1) months compared
to the group without therapy 24.0 (9.8-46.3) months (p<0.001). OMT duration remained a significant determinant
for treatment uptake when controlled for potential confounding. SVR was achieved in 25 out of 35 patients (71%).
Conclusion: In addicted patients a high CHC treatment and viral eradication rate in a primary care setting in
Switzerland is feasible. Opioid substitution seems a beneficial framework for CHC care in this “difficult to treat”
population.
Keywords: Hepatitis C, Methadone substitution, Primary care
Background
Chronic hepatitis C infection (CHC) is a major cause of
end-stage liver disease (ESLD). Injection drug users
(IDUs) are a major risk group for HCV infection [1] thus
they significantly contribute to the patient group with
ESLD in the future [2]. In recent years treatment efficacy
of CHC has been steadily increased and a successful
virus eradication can be achieved in up to 80% of
patients with genotype 2 and 3 and in about 50% of
patients chronically infected with genotype 1 [3-5].
However data suggest that about 70% of patients with
confirmed CHC go untreated [6-8] therefore reducing
therapeutic effectiveness of an anti-HCV therapy.
Increasing evidence suggests similar treatment efficacy
of a pegylated interferon-based (pegIFN) combination
therapy with ribavirin on HCV clearance in patients with
substance abuse compared to patients without drug de-
pendency [9-13]. Despite the revised NIH consensus on
medical management of HCV infection that recom-
mended a treatment decision on an individual basis [14]
current clinical practice suggests that CHC patients with
a history of IDU have a lower chance of getting antiviral
therapy compared to other patient groups [7,15]. This
further emphasize that the true therapeutic impact of an
anti-CHC therapy is rather an issue of access to treat-
ment than of drug efficacy.
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In IDUs concomitant illicit drug use, problem drink-
ing, comorbid medical (e.g. HIV) and psychiatric condi-
tions are prevalent representing common barriers to
antiviral treatment. On the other hand opioid mainten-
ance treatment (OMT) is established in the therapy of
substance abuse [16] and has been shown to be an ef-
fective framework for adherence and virological success
in HIV treatment [17,18]. In addition we previously
demonstrated the beneficial role of a substitution treat-
ment as a therapeutic framework for a successful CHC
case finding [19]. We hypothesized that a general practi-
tioner (GP) providing an integrated chronic care ap-
proach including an OMT can achieve similar CHC
treatment rates and viral eradication rates compared to
patients without drug dependency. In addition we aimed
to assess patient characteristics including duration of
OMT which were associated with CHC treatment initi-
ation in a primary care setting.
Methods
Patients and setting
Retrospective records review of patients receiving opioid
maintenance treatment (OMT) in the study period be-
tween January 1, 2002 through May 31, 2008. A detailed
description of the study population and the setting has
been previously reported elsewhere [19]. Briefly, all
patients ≥ 18 years old and participating for at least
3 months in an official office-based OMT programme run
by a single-handed general practice located in Zurich,
Switzerland were eligible for CHC assessment and evalu-
ation for antiviral therapy in the case of a CHC infection.
In 327 out of 360 patients (90.8%) on OMT a successful
CHC assessment could be performed and 85 out of the
327 patients (26%) were chronically infected with hepatitis
C. The OMT regimen (methadone, buprenorphine or
morphine) was based on a computer-assisted drug pre-
scription and delivery system (CDDD) that provides a pa-
tient tailored dosage regime within a safety framework
allowing the patients to choose dosage within an indivi-
dualised maximal daily dose [20]. The diagnosis of chronic
hepatitis C was based on a detectable HCV RNA concen-
tration and a reported HCV genotype performed by an
approved laboratory using a quantitative polymerase-chain
reaction. All patients had not been treated previously for
CHC. The practice staff has long experience and is specif-
ically trained in OMT and HCV care. All HCV treatments
were given in the general practice coordinated and super-
vised by the GP. A close collaboration within a network of
hepatologists, infectiologists and psychiatrists guaranteed
rapid access to spezialized care within less than three days.
Prior to the OMT and HCV screening patients were asked
for their informed consent in an anonymous data analysis.
Under Swiss ethics guidelines the study did not require a
formal ethics approval.
Treatment protocol
In all 85 CHC patients risks and opportunities of a spe-
cific antiviral therapy have been discussed. Patients
infected with HCV genotypes 1 and 4 were treated with
once-weekly injections of peginterferon alfa-2a (180 μg),
plus ribavirin (1000 mg or 1200 mg/day by weight in
divided dose) for 48 weeks. A treatment regimen of riba-
virin 800 mg/day (divided in two doses) and peginter-
feron alfa-2a 180 μg/week subcutaneously for 24 weeks
was used for patients with HCV genotype 3 (no patient
of the current study population was infected with geno-
type 2). Peginterferon injections were applied by the med-
ical staff of the general practice mostly while patients
received their substitution treatment. Direct dose adjust-
ments according to current treatment guidelines were pos-
sible as laboratory point-of care testing (differential blood
count) was available at the general practice. Ribavirin has
been distributed on a weekly basis in patients with good
compliance and a daytime structure (e.g. certificate of
employment) or on a daily observed treatment regimen.
Viremia was measured at week 12, at the end of treatment,
and 6 months after the end of treatment.
Prior to antiviral treatment start patients with poorly
controlled psychiatric disorders were stabilized by pharma-
cological therapies. A prophylactic treatment was started in
patients with a history of depressive disorder before begin-
ning an antiviral therapy. Patients were systematically
counselled for a reliable contraception and in women a
hormone-releasing intrauterine device (Mirena™) was rou-
tinely recommended. Substance abuse including injection
drug use was not an exclusion criteria for an interferon-
based therapy, however abstinence (or at least a substantial
reduction) of alcohol and concomitant substance abuse
was strongly recommended in all patients.
Outcome measures and assessments
Treatment rate and treatment success were primary out-
comes and defined as follow: The proportion of evaluated
CHC patients who started an interferon-based therapy
and the proportion of treated patients with a sustained vir-
ologic response (SVR) (i.e. undetectable HCV RNA in the
serum 6 months after end of treatment). Viral eradication
rate at the end of treatment (ETR) and SVR according to
genotypes and in HIV-coinfected patients were secondary
outcomes.
OMT-related data (i.e. duration, average dose) could
be accessed and further processed from CDDD (see
above). Demographics, psychiatric co-morbidities (based
on clinical grounds), self-declared addiction-specific
variables (i.e. history of IDU and current IDU, concomi-
tant problematic drug and alcohol abuse), and social-
and occupational characteristics (i.e. housing situation,
employability expressed as a percentage of a full time
aequivalent based on a certificate of employment) were
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assessed by systematic charts review. Problematic sub-
stance misuse including alcohol was defined on consensus
within the practice team based on clinical observation and
patients’ self-reports during routine daily or weekly OMT
provision. Substance users’ self-reports have been shown
to be reliable, especially in OMT programmes that assure
confidentiality and absence of adverse consequences [21].
Patients suffering from a severe adverse event related to a
psychiatric co-morbidity (e.g. suicidal behaviour, psychi-
atric hospitalisation) were considered as unstable.
Statistical analysis
Descriptive statistics were calculated for all variables.
Patients were categorized according to their history of
CHC treatment (i.e. “treatment start” vs. “no CHC treat-
ment”). Non-parametric group comparisons were per-
formed to test for differences in distributions of patient
characteristics. A multiple logistic regression was used to
further assess the independent associations between CHC
treatment history and patient characteristics. All statistical
analysis were performed using STATA for Windows
(version 10.1; Stata Corp., College Station, Texas).
Results
Baseline characteristics of the 85 patients receiving OMT
with a concomitant diagnosis of chronic hepatitis C
(CHC) are described in Table 1. Patients started substance
abuse on average at the age (IQR) of 18.6 (15.6-20.7) years.
Median (IQR) age and age entering the current OMT
programme was 38.8 (35.0-44.4) and 34.0 (30.2-39.6)
years, respectively. A vast majority of the patients (90.6%)
was on methadone maintenance treatment and 11 patients
(12.9%) experienced more than 1 opiate for long-term
substitution. The median (IQR) duration on OMT was
37.1 (14.5-72) months with a wide range between 4 to
310.9 months. During the study period median prescrip-
tion for methadone, buprenorphine and morphine was
72.8 (50.1-119.8), 6.2 (3.0-6.5), and 430.5 (312.1-514.8)
milligram, respectively. Psychiatric comorbidity was high
with about 40% suffering from an unstable disorder and
almost one third having a stable condition with or without
treatment. The majority of the patients (70.3%) suffering
from an unstable psychiatric disorder could have been re-
ferred for a psychiatric treatment. All of the referred
patients have been diagnosed with a mood disorder and
the majority (80.8%) of them suffered from a psychiatric
comorbide personality disorder. Former injection drug use
(IDU) was reported in the vast majority of the patients
and almost 20% reported current IDU. Problematic drug
abuse or excessive alcohol consumption was present in al-
most one third of the patients. Most of the patients had a
permanent residence with part- or fulltime employment.
HIV-co-infection prevalence was 20%.
CHC treatment rate and patient determinants for
treatment decision
In 35 patients out of the 85 CHC patients an antiviral
treatment with pegylated interferon and ribavirin was
started, corresponding to a treatment rate of 41.2%.
Group comparisons between patients who started a ther-
apy and patients who disagreed to a HCV treatment are
presented in Table 2. Duration of OMT was significantly
longer in patients who started an antiviral therapy. This
association remained statistically significant and revealed
an odds ratio (95% CI) of 1.020 (1.006-1.04) (p=0.01)
when controlling for potential confounders in a multiple
logistic regression. There was no evidence of a non-linear
Table 1 Characteristics of CHC patients >3 months on
opioid maintenance treatment (OMT)
Demographics % (n)* or median
[IQR] (n)*
Male 61.2 (52)
Age (years) 38.8 (35.0-44.4)
Opioid maintenance therapy (OMT):
Age beginning substance abuse (years) 18.3 (15.6-20.7)
Age beginning the current OMT (years) 34.0 (30.2-39.6)
Methadone as last OMT medication 90.6 (77)
Buprenorphin as last OMT medication 4.7 [4]
Morphin as last OMT medication 4.7 [4]
Use of ≥1 different opioid in the past 12.9 [11]
Duration of OMT (months) 37.1 (14.5-72)
Average methadone dose during OMT (mg) 72.8 (50.1-119.8)
Psychiatric comorbidity:
No psychiatric disorder 28.2 [24]
Stable disorder without treatment 12.9 [11]
Stable disorder under treatment 15.3 [13]
Unstable disorder 43.5 (37)
Injection drug use (IDU):
In the past 92.9 (79)
Current 17.7 [15]
Other drug and excessive alcohol use:
Heroin 27.1 [23]
Cocaine 25.9 [22]
Benzodiazepines 20.2 [17]
Alcohol 31.8 [27]
Occupational and housing variables:
Employability (%) 60 (30–100)
Single household 54.1 (46)
Shared household 36.5 (31)
Other lodging # 9.4 [8]
HIV-co-infection
HIV positive 20 [16]*
*Total number of patients= 85; HIV status was missing in 5 patients; #lodging
of patients without stable housing was as follows: homeless [2], asylum [2],
social institutions [2], accommodation by friends [2].
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relationship between OMT duration and treatment
uptake. The most frequent reason against CHC treatment
was patient refusal in 40 cases (80%). No treatment was
performed due to various somatic reasons in the remaining
10 patients (20%).
CHC treatment success
In 25 out of 35 patients who started a CHC treatment no
HCV-RNA could be detected 6 months after the end of
treatment corresponding to a sustained virological re-
sponse rate (SVR) of 71%. Three patients with successful
Table 2 Determinants of CHC treatment decision in CHC patients >3 months on OMT
Determinants Treatment start (n=35) No CHC treatment (n=50) P-value*
% (n) or median [IQR] % (n) or median [IQR]
Demographics:
Male 65.7 [23] 58 [29]
Female 34.3 [12] 42 [21] 0.48
Age (years) 41.8 (37.2-45.1) 37.5 (34.8-43.8) 0.06
Age beginning OMT (years) 35.0 (31.9-39.9) 33.4 (29.2-39.1) 0.45
Opiate maintenance therapy:
Methadone 88.5 (31) 92 (46)
Buprenorphin 8.6 [3] 2 [1]
Morphin 2.9 [1] 6 [3] 0.51
Single OMT therapy 88.6 (31) 86 (43)
Use of ≥1 different opiate in the past 11.4 [4] 14 [7] 1.0
Duration of OMT (months) 55.0 (35.0-110.1) 24.0 (9.8-46.3) <0.001#
Average methadone dose during OMT (mg) 73 (50–120) 73 (50–122) 0.83
Psychiatric comorbidity:
None or stable disorder 68.6 [24] 52 [24]
Unstable disorder 31.4 [11] 48 [26] 0.060
Injection drug use (IDU):
In the past, yes 91 (32) 94 (47)
In the past, no 9 [3] 6 [3] 0.69
Current, yes 8.6 [3] 24 [12]
Current, no 91.4 (32) 76 (38) 0.086
Other drug and excessive alcohol use:
Current heroin use 20 [7] 32 [16]
No heroin use 80 [28] 68 (34) 0.22
Current cocaine use 25.7 [9] 26 [13]
No cocaine use 74.3 [26] 74 (37) 0.98
Current benzodiazepine use 14.7 [5] 26 [12]
No benzodiazepine use 85.3 [29] 74 (38) 0.41
Excessive alcohol use 28.6 [10] 34 [17]
No alcohol excess 71.4 [25] 66 (33) 0.60
Occupational and housing variables:
Employability (%) 60 (30–100) 60 (30–100) 0.52
Single household 40 [14] 34 [17]
Shared household 51.4 [18] 56 [28]
Other lodging 8.6 [3] 10 [5] 0.90
HIV-co-infection†
HIV positive 14.7 [5] 23.9 [11]
HIV negative 85.3 [29] 76.1 (35) 0.40
*Group comparisons by Chi-square or Fisher exact as appropriate and Mann–Whitney test;
# remained independently associated with treatment start after controlling for age, sex, psychiatric comorbidity, IDU, drug and alcohol use, employability, housing
and HIV-co-infection with an OR (95% CI) of 1.02 (1.006-1.04) (p=0.01); †HIV-status was missing in 5 patients.
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HCV-clearance after initial treatment suffered from a re-
lapse, corresponding to a success rate at the end of treat-
ment of 80% (28/35). When stratified according to HCV
genotypes SVR was 76.% in genotype 3 (10 out of 13
patients), 73.7% in genotype 1 (14 out of 19 patients), and
33.3% in genotype 4 (1 out of 3 patients). In 3 out of the 5
HIV-co-infected patients a SVR could be achieved.
Reasons for a failure of pegIFN+RBV in the 10 patients
starting an antiviral therapy were as follow: non-responder
(n=6), relapse (n=3), early treatment stop due to medical
reasons (n=1).
Discussion
This study examined CHC treatment and success rates
in unselected patients appearing “difficult to treat” in a
single-handed general practice in Switzerland. Although
a substantial proportion of the study population suffered
from psychiatric comorbidities, reported excessive alcohol
consumption and current drug misuse including injection
drug use, treatment could be started in 41.2% and resulted
in an overall sustained virological response rate of 71%.
The duration of OMT was associated independently and
positively with the start of a CHC treatment.
The observed treatment rate compares favourably with
previous studies although comparisons have to be inter-
preted with caution as patient populations differ greatly
across studies. In a UK population of CHC patients,
Irving et al. [22] reported an overall treatment rate of
10.2% with a wide range varying according to the source
of original HCV screening test with the highest rate of
21.4% in patients referred from GPs and a treatment rate
of only 1.6% in patients originally screened for HCV by
specialist units for drug and alcohol. Butt and colleagues
[23] found a treatment rate of 11.8% in unselected veter-
ans who were older (median age 50 years) compared to
our study sample but comparable with regard to the
prevalence of comorbidities such as psychiatric disorders
and drug and alcohol dependence. The cumulative
chance of starting CHC treatment in a 5 year period has
been estimated to 33% in a representative Danish CHC
cohort study [24]. Among patients attending the special-
ist consultations of the Swiss Hepatitis C Cohort Study
(SDDS) [25] a history of CHC related treatment has
been reported in 31% of the whole cohort and in 51% in
the subgroup of cirrhotics. We found an independent
and positive association between treatment initiation
and the duration of OMT. Thus a patient spending
37 months (i.e. the median duration of OMT in our
study population) on opioid substitution has doubled
the chance ( i.e. OR 1.0237 months =2.0) of getting started
CHC treatment compared to a patient simply fulfilling
the inclusion criteria of minimum 3 months on substitu-
tion. This beneficial effect of OMT has already been shown
to increase adherence and virological success in HIV
treatment [16,18] and is in line with the finding that an on-
going OMT significantly increased the chance of a success-
ful CHC case finding [19]. We are not aware of a study
that has assessed the specific role of an OMT programme
in the context of CHC treatment initiation. Our results fur-
ther strengthened OMTas a favourable therapeutic setting,
expanding its role for HCV-related care.
We achieved a viral eradication rate similar compared
to randomized controlled efficacy trials reporting a sus-
tained virological response up to 80% of patients with
genotype 2 and 3 and in about 50% of patients chronic-
ally infected with genotype 1 [3-5]. The selection criteria
for the aforementioned multicenter registration trials
however excluded IDUs thus although internal validity
of these studies is high illicit drug users constitute the
largest proportion of CHC patients and the results do
not represent treatment effectiveness in a “real world
setting”. Our response rate is in line with a recent meta-
analysis suggesting similar treatment efficacy of an anti-
viral therapy on HCV clearance in patients receiving
OMT compared to patients without drug dependency
[9]. However in only 3 out of the 16 studies included in
the aforementioned meta-analysis active ongoing illicit
drug use was not an exclusion criteria thus our results
provided further evidence that successful viral eradica-
tion is feasible in a population normally excluded from
clinical trials and judged “difficult to treat”.
We are aware that the analysis of our study does not
address the CHC treatment effectiveness of a primary
care setting in comparison to a specialized medical care
setting due to the lack of a randomised controlled inter-
vention. The current standard of care for the treatment
of chronic HCV infection which is also recommended
for patients with substance abuse was applied by the
attending GP with a high level of commitment and a
special interest in addiction medicine. Providing chronic
care (i.e. substitution, psychiatric comorbidities) in com-
bination with acute somatic care is a main feature of a pri-
mary care setting. Our treatment rate is in line with a
recent randomized controlled study evaluating the impact
of an integrated care approach among CHC patients ori-
ginally deferred from CHC therapy due to mental health
and substance abuse comorbidities [26]. In this study
patients receiving an integrated care intervention reached
a treatment eligibility of 42% compared to the standard
care group with a significant lower eligibility rate of 18%.
In our population the level of homelessness and un-
employment was relatively low but similar when com-
pared to GP patients in other OMT programmes in
Switzerland, which probably reflects the low-threshold
management of drug addicts in Switzerland [27]. Further-
more it is important to note that an OMT durationof
fewer than 3 months was an exclusion criteria thus a se-
lection of our population probably related to a high level
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of integration in the social framework has to be consid-
ered when compared to other settings.
From a clinical perspective the development of new
direct acting antiviral agents such as the protease inhibi-
tors boceprevir and telaprevir are long-awaited and their
implementation to clinical practice in the near future
have the potential for a new standard of care for the
treatment of chronic hepatitis C [28]. Although these
new antiviral agents showed superior cure rates com-
pared to the current standard of care the public health
impact of these new and better medications will remain
limited unless more patients are diagnosed and treat-
ment is initiated [29,30]. To control chronic hepatitis C
an increase in treatment uptake is crucial especially in
the population of (former) IDUs as these patients have by
far the highest prevalence of hepatitis C. On the other
hand barriers to HCV-related care are most likely in this
“hard to reach” population. An easy to access antiviral
treatment linked to OMT has the potential to optimize
treatment and cure rates in this “hard to reach” popula-
tion. We provided a successful example of a low-threshold
HCV-related care in a Swiss primary care setting.
Conclusions
We conclude that a high rate of CHC eradication in unse-
lected patients on OMT is feasible in a primary care set-
ting in Switzerland. The independent association between
OMT duration and treatment initiation highlights the im-
portant role of opioid substitution as a therapeutic frame-
work to optimize CHC care in a patient group that
significantly contributes to the global burden of liver dis-
eases caused by HCV infection.
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